
  
    
      
        Background_NNP
        Since_IN the_DT publication_NN of_IN the_DT Diabetes_NNP Control_NNP and_CC
        Complications_NNP Trial_NNP results_NNS demonstrating_VBG the_DT efficacy_NN of_IN
        intense_JJ glycemic_JJ control_NN using_VBG insulin_NN therapy_NN and_CC frequent_JJ
        self-monitoring_JJ of_IN blood_NN glucose_NN (_( SMBG_NNP )_) in_IN improving_VBG health_NN
        outcomes_NNS ,_, [_NN 1_CD ]_NN SMBG_NNP has_VBZ become_VBN a_DT principal_JJ component_NN of_IN
        diabetes_NN management_NN ._. While_IN the_DT efficacy_NN of_IN self-monitoring_JJ
        independent_JJ of_IN other_JJ self-management_JJ practices_NNS is_VBZ still_RB
        uncertain_JJ ,_, the_DT practice_NN is_VBZ recommended_VBN for_IN patients_NNS using_VBG
        either_CC insulin_NN or_CC oral_JJ drug_NN therapy_NN ._. [_NN 2_CD ]_NN As_IN a_DT result_NN ,_,
        managed_VBN care_NN organizations_NNS (_( MCOs_NNP )_) are_VBP under_IN increasing_VBG
        pressure_NN to_TO cover_VB the_DT cost_NN of_IN self-monitoring_JJ equipment_NN [_NN 3_CD
        ]_NN and_CC to_TO improve_VB rates_NNS of_IN SMBG_NNP among_IN their_PRP$ diabetes_NN
        patients_NNS ._. [_NN 4_CD ]_NN
        In_IN addition_NN to_TO logistic_JJ barriers_NNS to_TO SMBG_NNP [_NN 5_CD ]_NN ,_, some_DT
        recent_JJ evidence_NN suggests_VBZ that_DT adult_NN diabetes_NN patients_NNS who_WP
        may_MD be_VB at_IN greatest_JJS risk_NN for_IN poor_JJ outcomes_NNS (_( e_SYM ._. g_SYM ._. ,_,
        minorities_NNS ,_, elderly_JJ ,_, lower_JJR SES_NNP )_) may_MD be_VB least_JJS likely_JJ to_TO
        self-monitor_JJ ._. [_NN 4_CD 6_CD ]_NN In_IN a_DT study_NN of_IN more_JJR than_IN 44_CD ,_, 000_CD
        managed_VBN care_NN patients_NNS with_IN type_NN 1_CD (_( 2_CD ,_, 818_CD )_) and_CC type_NN 2_CD
        (_( 41_CD ,_, 363_CD )_) diabetes_NN ,_, Karter_NNP et_CC al_NN [_NN 4_CD ]_NN identified_VBN older_JJR age_NN ,_,
        male_JJ gender_NN ,_, non-white_JJ race_NN ,_, lower_JJR socioeconomic_JJ status_NN ,_,
        English_NNP language_NN difficulty_NN ,_, higher_JJR out_IN of_IN pocket_NN test_NN
        strip_NN costs_NNS ,_, intensity_NN of_IN insulin_NN therapy_NN ,_, greater_JJR alcohol_NN
        consumption_NN ,_, and_CC smoking_NN as_IN independent_JJ predictors_NNS of_IN less_RBR
        frequent_JJ self-monitoring_JJ in_IN diabetes_NN patients_NNS ._. This_DT study_NN
        was_VBD the_DT first_JJ to_TO move_VB beyond_IN simple_JJ reporting_NN of_IN
        descriptive_JJ statistics_NNS in_IN order_NN to_TO assess_VB predictors_NNS of_IN
        SMBG_NNP in_IN managed_VBN care_NN settings_NNS ._. Unfortunately_RB ,_, the_DT validity_NN
        of_IN the_DT study_NN findings_NNS is_VBZ limited_VBN by_IN the_DT reliance_NN on_IN
        self-reports_JJ of_IN self-monitoring_JJ ,_, an_DT unreliable_JJ measure_NN of_IN
        actual_JJ behavior_NN ._. [_NN 7_CD ]_NN
        The_DT purpose_NN of_IN the_DT current_JJ study_NN was_VBD to_TO examine_VB the_DT
        relationship_NN between_IN patient_NN characteristics_NNS and_CC SMBG_NNP in_IN a_DT
        large_JJ health_NN maintenance_NN organization_NN (_( HMO_NNP )_) using_VBG objective_NN
        measures_NNS of_IN self-monitoring_JJ practice_NN ._. Specifically_RB ,_, we_PRP
        tested_VBD the_DT hypothesis_NNS that_IN ,_, controlling_VBG for_IN type_NN of_IN drug_NN
        therapy_NN and_CC severity_NN of_IN illness_NN ,_, diabetes_NN patients_NNS at_IN
        greatest_JJS risk_NN for_IN poor_JJ health_NN outcomes_NNS (_( e_SYM ._. g_SYM ._. ,_, older_JJR age_NN ,_,
        multiple_JJ chronic_JJ conditions_NNS ,_, non-white_JJ race_NN ,_, lower_JJR
        neighborhood_NN SES_NNP )_) are_VBP less_RBR likely_JJ to_TO practice_VB SMBG_NNP ._. The_DT
        study_NN population_NN included_VBD more_JJR than_IN 4_CD ,_, 500_CD adult_NN managed_VBD
        care_NN patients_NNS using_VBG insulin_NN ,_, oral_JJ ,_, or_CC a_DT combination_NN of_IN the_DT
        two_CD drug_NN therapies_NNS ._. Our_PRP$ use_NN of_IN objective_NN measures_NNS of_IN SMBG_NNP
        distinguishes_NNS this_DT study_NN from_IN previous_JJ attempts_NNS to_TO identify_VB
        predictors_NNS of_IN SMBG_NNP in_IN managed_VBN care_NN ._. This_DT paper_NN represents_VBZ
        the_DT first_JJ phase_NN of_IN a_DT larger_JJR study_NN to_TO evaluate_VB the_DT effect_NN of_IN
        distributing_VBG free_JJ home_NN glucose_NN monitors_VBZ to_TO diabetes_NN
        patients_NNS at_IN this_DT New_NNP England_NNP HMO_NNP ._.
      
      
        Methods_NNP
        
          Study_NNP Setting_VBG and_CC Data_NNP Sources_NNS
          Harvard_NNP Vanguard_NNP Medical_NNP Associates_NNPS (_( HVMA_NNP )_) is_VBZ a_DT
          multi-specialty_JJ group_NN practice_NN serving_VBG nearly_RB 300_CD ,_, 000_CD
          people_NNS in_IN diverse_JJ ethnic_JJ and_CC socioeconomic_JJ communities_NNS in_IN
          and_CC around_IN Boston_NNP ,_, Massachusetts_NNP ._. At_IN the_DT time_NN of_IN the_DT
          study_NN ,_, nearly_RB all_DT of_IN the_DT patients_NNS at_IN HVMA_NNP 's_POS fourteen_CD
          health_NN centers_NNS were_VBD insured_VBN in_IN Harvard_NNP Pilgrim_NNP Health_NNP
          Care_NNP (_( HPHC_NNP )_) ,_, one_CD of_IN the_DT largest_JJS HMOs_NNP in_IN New_NNP England_NNP ._. Home_NN
          glucose_NN monitoring_VBG test_NN strips_NNS were_VBD covered_VBN by_IN HPHC_NNP and_CC
          all_DT members_NNS had_VBD coverage_NN for_IN prescription_NN medications_NNS ._.
          The_DT automated_VBN medical_JJ records_NNS system_NN (_( AMRS_NNP )_) at_IN HVMA_NNP /_NN HPHC_NNP
          captured_VBD data_NNS from_IN all_DT ambulatory_JJ and_CC inpatient_NN
          encounters_VBZ between_IN plan_NN members_NNS and_CC providers_NNS in_IN a_DT
          combination_NN of_IN both_DT coded_VBN and_CC narrative_NN fields_NNS ._. The_DT AMRS_NNP
          has_VBZ been_VBN previously_RB used_VBN for_IN research_NN purposes_NNS ._. [_NN 8_CD 9_CD ]_NN
          In_IN addition_NN to_TO AMRS_NNP data_NNS ,_, we_PRP mapped_VBN patients_NNS '_POS addresses_NNS
          to_TO census_NN tract_NN information_NN to_TO control_VB for_IN the_DT
          socioeconomic_JJ characteristics_NNS of_IN the_DT patient_NN 's_POS
          neighborhood_NN of_IN residence_NN ._.
        
        
          Study_NNP Cohort_NNP
          In_IN order_NN to_TO be_VB eligible_JJ for_IN inclusion_NN in_IN the_DT study_NN ,_,
          patients_NNS had_VBD to_TO be_VB at_IN least_JJS 18_CD years_NNS old_JJ and_CC to_TO have_VB been_VBN
          diagnosed_VBN with_IN diabetes_NN or_CC to_TO have_VB received_VBN at_IN least_JJS one_CD
          prescription_NN for_IN insulin_NN or_CC an_DT oral_JJ sulfonylurea_NN at_IN some_DT
          time_NN between_IN December_NNP 1_CD ,_, 1991_CD and_CC November_NNP 30_CD ,_, 1993_CD ._. This_DT
          study_NN represents_VBZ the_DT first_JJ phase_NN in_IN an_DT evaluation_NN of_IN the_DT
          implementation_NN of_IN a_DT policy_NN to_TO provide_VB free_JJ home_NN glucose_NN
          monitors_VBZ to_TO HPHC_NNP patients_NNS ._. All_DT data_NNS for_IN this_DT study_NN were_VBD
          collected_VBN from_IN medical_JJ records_NNS covering_VBG the_DT year_NN
          preceding_VBG the_DT policy_NN change_NN (_( 10_CD /_NN 1_CD /_NN 92_CD -_: 9_CD /_NN 30_CD /_NN 93_CD )_) ._. For_IN
          continuity_NN of_IN the_DT study_NN cohort_NN ,_, we_PRP included_VBD only_RB those_DT
          patients_NNS with_IN no_RB more_JJR than_IN 45_CD days_NNS disenrollment_NN between_IN
          01_CD /_NN 01_CD /_NN 92_CD and_CC 09_CD /_NN 30_CD /_NN 95_CD ._. Patients_NNS with_IN gestational_JJ diabetes_NN
          were_VBD excluded_VBN ._.
        
        
          Dependent_NNP Variables_NNP
          Our_PRP$ outcomes_NNS of_IN interest_NN were_VBD the_DT likelihood_NN of_IN 
          any_DT SMBG_NNP and_CC 
          regularity_NN of_IN SMBG_NNP once_RB initiated_VBD ._.
          Patients_NNS were_VBD classified_VBN as_IN having_VBG ever_RB self-monitored_JJ if_IN
          they_PRP filled_VBD at_IN least_JJS one_CD prescription_NN for_IN self-monitoring_JJ
          test_NN strips_NNS during_IN the_DT study_NN period_NN ._. Test_NN strip_NN use_NN has_VBZ
          been_VBN employed_VBN in_IN previous_JJ studies_NNS as_IN a_DT reliable_JJ indicator_NN
          of_IN actual_JJ SMBG_NNP in_IN diabetes_NN patients_NNS ._. [_NN 10_CD 11_CD 12_CD ]_NN As_IN only_RB
          a_DT very_RB small_JJ number_NN of_IN patients_NNS were_VBD using_VBG urine_NN test_NN
          strips_NNS to_TO monitor_VB glycemic_JJ levels_NNS (_( 1_CD ._. 5_LS %_NN )_) ,_, we_PRP did_VBD not_RB
          include_VB urine_NN testing_NN as_IN a_DT measure_NN of_IN
          self-monitoring_JJ ._.
          Regular_JJ SMBG_NNP among_IN patients_NNS with_IN any_DT test_NN strip_NN use_NN
          was_VBD defined_VBN as_IN filling_VBG prescriptions_NNS for_IN 90_CD or_CC more_JJR test_NN
          strips_NNS per_IN quarter_NN (_( i_NNP ._. e_SYM ._. ,_, testing_VBG an_DT average_NN of_IN at_IN least_JJS
          once_RB per_IN day_NN )_) for_IN those_DT using_VBG insulin_NN or_CC combination_NN
          therapy_NN ,_, and_CC 45_CD or_CC more_JJR per_IN quarter_NN (_( i_NNP ._. e_SYM ._. ,_, testing_VBG an_DT
          average_NN of_IN at_IN least_JJS once_RB every_DT other_JJ day_NN )_) for_IN those_DT using_VBG
          oral_JJ sulfonylureas_NNS only_RB ._. Cut_VB points_NNS for_IN regular_JJ use_NN were_VBD
          based_VBN on_IN dispensing_VBG patterns_NNS and_CC recent_JJ guidelines_NNS
          recommending_VBG testing_NN three_CD to_TO four_CD times_NNS per_IN day_NN for_IN
          insulin_NN users_NNS and_CC less_RBR frequent_JJ testing_NN for_IN non-insulin_JJ
          users_NNS ._. [_NN 2_CD ]_NN We_PRP assumed_VBD that_IN test_NN strips_NNS were_VBD used_VBN evenly_RB
          over_IN the_DT period_NN between_IN test_NN strip_NN dispensings_NNS ._. Test_NN
          strips_NNS were_VBD prorated_JJ over_IN a_DT minimum_NN of_IN 30_CD days_NNS if_IN the_DT
          next_JJ dispensing_VBG occurred_VBN sooner_RBR than_IN that_DT ,_, and_CC over_IN a_DT
          maximum_NN of_IN 60_CD days_NNS if_IN there_EX was_VBD no_DT subsequent_JJ dispensing_VBG
          during_IN that_DT period_NN ._. Multivariate_NNP analyses_NNS were_VBD limited_VBN to_TO
          patients_NNS using_VBG drug_NN therapy_NN and_CC stratified_JJ by_IN type_NN of_IN
          drug_NN therapy_NN (_( i_NNP ._. e_SYM ._. ,_, insulin_NN alone_RB or_CC with_IN sulfonylureas_NNS ,_,
          sulfonylureas_NNS only_RB )_) ._.
        
        
          Independent_NNP Variables_NNP
          We_PRP identified_VBD variables_NNS in_IN the_DT AMRS_NNP that_WDT represented_VBD
          factors_NNS that_WDT may_MD influence_VB preventive_JJ health_NN behavior_NN [_NN
          13_CD ]_NN as_RB well_RB as_IN those_DT identified_VBN in_IN the_DT literature_NN as_IN
          being_VBG predictive_JJ of_IN SMBG_NNP ._. [_NN 4_CD 6_CD ]_NN Available_NNP demographic_JJ
          information_NN included_VBD gender_NN ,_, age_NN ,_, race_NN ,_, and_CC Medicare_NNP or_CC
          Medicaid_NNP insurance_NN status_NN as_IN recorded_VBN by_IN the_DT provider_NN or_CC
          health_NN plan_NN ._. Given_VBN the_DT small_JJ numbers_NNS of_IN other_JJ minority_NN
          groups_NNS at_IN HVMA_NNP ,_, we_PRP combined_VBD all_DT racial_JJ groups_NNS other_JJ than_IN
          white_JJ or_CC black_JJ into_IN a_DT single_JJ category_NN labeled_VBD other_JJ ._. We_PRP
          then_RB created_VBD two_CD dichotomous_JJ variables_NNS ,_, black_JJ and_CC other_JJ ,_,
          with_IN white_JJ race_NN as_IN the_DT reference_NN group_NN ._.
          Census_NNP tract_NN level_NN data_NNS were_VBD used_VBN to_TO represent_VB the_DT
          socioeconomic_JJ status_NN of_IN the_DT patient_NN and_CC their_PRP$
          neighborhood_NN of_IN residence_NN ._. We_PRP created_VBD an_DT index_NN composed_VBN
          of_IN the_DT sum_NN of_IN four_CD weighted_JJ census_NN tract_NN measures_NNS (_( i_NNP ._. e_SYM ._. ,_,
          percent_NN with_IN a_DT college_NN education_NN ,_, median_JJ household_NN
          income_NN ,_, percent_NN of_IN households_NNS in_IN which_WDT English_NNP was_VBD the_DT
          primary_JJ language_NN ,_, and_CC percent_NN home_NN ownership_NN )_) ._. The_DT
          variables_NNS included_VBN in_IN the_DT index_NN were_VBD standardized_JJ for_IN
          summation_NN by_IN centering_VBG them_PRP around_IN a_DT mean_NN of_IN zero_CD ._. Their_PRP$
          relative_JJ weightings_NNS in_IN the_DT index_NN were_VBD determined_VBN using_VBG
          factor_NN analysis_NN ._. Among_IN several_JJ measures_NNS created_VBN from_IN
          census_NN tract_NN variables_NNS to_TO measure_VB neighborhood_NN SES_NNP ,_, the_DT
          index_NN created_VBD using_VBG the_DT factor_NN analysis_NN approach_NN proved_VBD
          to_TO be_VB the_DT strongest_JJS predictor_NN of_IN SMBG_NNP in_IN univariate_NN
          analyses_NNS ._.
          Clinical_NNP assessments_NNS of_IN health_NN status_NN as_IN measures_NNS of_IN
          susceptibility_NN or_CC potential_JJ for_IN the_DT threat_NN of_IN poor_JJ health_NN
          outcomes_NNS included_VBD two_CD dichotomous_JJ measures_NNS of_IN body_NN mass_NN
          index_NN [_NN 14_CD ]_NN (_( i_NNP ._. e_SYM ._. ,_, overweight_NN :_: 25_CD kg_NN /_NN m_NN 2_CD <_NN BMI_NNP <_NN 30_CD
          kg_NN /_NN m_NN 2_CD ;_: obese_NN :_: BMI_NNP ≥_NN 30_CD kg_NN /_NN m_NN 2_LS )_) and_CC an_DT age-_NN and_CC
          gender-weighted_JJ chronic_JJ disease_NN score_NN (_( CDS_NNP )_) [_NN 15_CD ]_NN based_VBN
          on_IN the_DT presence_NN or_CC absence_NN of_IN 29_CD specific_JJ comorbidities_NNS
          determined_VBN from_IN pharmacy_NN dispensing_VBG data_NNS ._. In_IN several_JJ HMO_NNP
          settings_NNS ,_, the_DT CDS_NNP has_VBZ performed_VBN as_RB well_RB or_CC better_JJR than_IN
          Ambulatory_NNP Disease_NNP Groups_NNS as_IN a_DT measure_NN of_IN illness_NN
          severity_NN ,_, explaining_VBG 50_CD -_: 60_CD %_NN of_IN variation_NN in_IN health_NN care_NN
          utilization_NN ,_, costs_NNS ,_, and_CC mortality_NN ._. [_NN 16_CD ]_NN We_PRP included_VBD
          deciles_NNS of_IN the_DT CDS_NNP in_IN multivariate_NN regression_NN analyses_NNS ._.
          We_PRP categorized_VBN the_DT last_RB recorded_VBN HbA_NNP 1_CD c_SYM test_NN value_NN for_IN
          each_DT individual_NN into_IN two_CD dichotomous_JJ measures_NNS
          representing_VBG poor_JJ and_CC very_RB poor_JJ glycemic_JJ control_NN (_( i_NNP ._. e_SYM ._. ,_,
          poor_JJ :_: HbA_NNP 1_CD c_SYM >_NN 8_CD ._. 0_CD %_NN ;_: very_RB poor_JJ :_: HbA_NNP 1_CD c_SYM >_NN 10_CD %_NN )_) ,_, with_IN
          HbA_NNP 1_CD c_SYM ≤_NN 8_CD ._. 0_CD as_IN the_DT reference_NN group_NN ._.
          Average_JJ standard_JJ monthly_JJ dose_NN of_IN oral_JJ diabetes_NN
          medication_NN used_VBN was_VBD also_RB included_VBN as_IN an_DT indicator_NN of_IN
          severity_NN of_IN illness_NN ._. These_DT standardized_JJ measures_NNS were_VBD
          constructed_VBN by_IN first_JJ calculating_VBG median_JJ monthly_JJ dose_NN of_IN
          each_DT drug_NN type_NN received_VBD in_IN the_DT entire_JJ study_NN cohort_NN during_IN
          the_DT study_NN period_NN ._. The_DT actual_JJ dose_NN received_VBD in_IN a_DT month_NN
          divided_VBN by_IN this_DT median_JJ dose_NN yielded_VBD a_DT standardized_JJ
          monthly_JJ amount_NN for_IN each_DT patient_NN ._. We_PRP then_RB calculated_VBD the_DT
          median_NN of_IN these_DT patient-level_JJ standardized_JJ measures_NNS for_IN
          the_DT year_NN and_CC included_VBD it_PRP as_IN a_DT covariate_NN in_IN the_DT
          multivariate_NN analyses_NNS ._.
          Dichotomous_NNP variables_NNS representing_VBG the_DT number_NN of_IN HbA_NNP 1_CD c_SYM
          lab_NN tests_NNS (_( =_SYM 1_CD if_IN #_# tests_NNS ≥_NN 2_LS )_) and_CC the_DT number_NN of_IN
          physician_NN visits_NNS (_( =_SYM 1_CD if_IN #_# visits_NNS ≥_NN 4_LS )_) were_VBD included_VBN as_IN
          measures_NNS of_IN predisposition_NN to_TO use_VB health_NN services_NNS ._. The_DT
          HVMA_NNP primary_JJ care_NN site_NN ,_, defined_VBN as_IN the_DT health_NN center_NN
          where_WRB at_IN least_JJS 75_CD %_NN of_IN outpatient_NN visits_NNS occurred_VBD (_( defined_VBN
          for_IN 78_CD %_NN of_IN patients_NNS )_) ,_, was_VBD included_VBN as_IN a_DT fixed_VBN effect_NN to_TO
          control_VB for_IN variations_NNS in_IN practice_NN patterns_NNS ._. As_IN the_DT vast_JJ
          majority_NN of_IN patients_NNS (_( >_NN 96_CD %_NN )_) paid_VBD a_DT $_$ 5_CD copayment_NN for_IN
          test_NN strips_NNS during_IN the_DT study_NN period_NN ,_, cost_NN to_TO the_DT patient_NN
          was_VBD not_RB included_VBN as_IN a_DT covariate_NN of_IN interest_NN ._.
        
        
          Statistical_NNP Analysis_NNP
          Statistical_NNP analyses_NNS were_VBD carried_VBN out_IN using_VBG SAS_NNP V_NNP 8_CD ._. 04_CD ._.
          [_NN 17_CD ]_NN All_DT analyses_NNS were_VBD stratified_JJ by_IN type_NN of_IN drug_NN
          therapy_NN (_( none_NN ,_, insulin_NN alone_RB or_CC in_IN combination_NN with_IN oral_JJ
          sulfonylureas_NNS ,_, and_CC oral_JJ sulfonylureas_NNS only_RB )_) in_IN accordance_NN
          with_IN the_DT literature_NN which_WDT suggests_VBZ greater_JJR rates_NNS of_IN
          monitoring_VBG among_IN those_DT using_VBG insulin_NN therapy_NN ._. [_NN 18_CD 19_CD 20_CD
          ]_NN We_PRP used_VBD chi-square_JJ tests_NNS to_TO compare_VB baseline_NN
          differences_NNS in_IN demographic_JJ status_NN and_CC health_NN care_NN
          utilization_NN by_IN type_NN of_IN drug_NN therapy_NN ,_, and_CC in_IN glycemic_JJ
          control_NN by_IN level_NN of_IN SMBG_NNP (_( e_SYM ._. g_SYM ._. ,_, none_NN ,_, any_DT ,_, regular_JJ use_NN )_) ._.
          For_IN patients_NNS using_VBG either_CC form_NN of_IN drug_NN therapy_NN ,_, we_PRP used_VBD
          logistic_JJ regression_NN to_TO estimate_VB the_DT factors_NNS associated_VBN
          with_IN the_DT likelihood_NN of_IN initiating_VBG SMBG_NNP and_CC regularity_NN of_IN
          SMBG_NNP for_IN those_DT with_IN some_DT test_NN strip_NN use_NN ._. We_PRP first_RB
          examined_VBD the_DT univariate_NN relationships_NNS between_IN each_DT
          candidate_NN predictor_NN and_CC our_PRP$ two_CD SMBG_NNP outcomes_NNS ._. Age_NNP ,_,
          gender_NN ,_, chronic_JJ disease_NN score_NN ,_, the_DT number_NN of_IN HbA_NNP 1_CD c_SYM tests_NNS ,_,
          and_CC primary_JJ care_NN location_NN were_VBD controlled_VBN for_IN in_IN all_DT
          models_NNS ._. Other_JJ variables_NNS were_VBD included_VBN in_IN the_DT multivariate_NN
          models_NNS if_IN univariate_NN p-values_JJ fell_VBD below_IN 0_CD ._. 20_CD ._. We_PRP used_VBD
          backward_RB selection_NN to_TO remove_VB variables_NNS not_RB significant_JJ at_IN
          the_DT ._. 05_CD level_NN ._. Overall_RB model_NN fit_NN ,_, including_VBG the_DT necessity_NN
          for_IN interaction_NN terms_NNS ,_, was_VBD ascertained_JJ using_VBG likelihood_NN
          ratio_NN statistics_NNS ._. [_NN 21_CD ]_NN Tests_NNP of_IN mixed_JJ (_( i_NNP ._. e_SYM ._. ,_,
          hierarchical_JJ or_CC random_JJ effects_NNS )_) models_NNS ,_, [_NN 22_CD ]_NN where_WRB
          census_NN tract_NN was_VBD defined_VBN as_IN a_DT higher-level_JJ random_JJ effect_NN ,_,
          produced_VBD no_DT evidence_NN of_IN clustering_VBG at_IN the_DT census_NN tract_NN
          level_NN ,_, indicating_VBG that_IN the_DT fixed_VBN effects_NNS approach_NN was_VBD
          adequate_JJ ._.
        
      
      
        Results_NNS
        
          Characteristics_NNP of_IN the_DT Sample_NNP
          The_DT total_JJ study_NN sample_NN consisted_VBD of_IN 4_CD ,_, 565_CD patients_NNS ,_,
          among_IN whom_WP 30_CD %_NN used_VBD no_DT drug_NN therapy_NN ,_, 31_CD %_NN used_VBD insulin_NN
          therapy_NN alone_RB or_CC in_IN combination_NN with_IN oral_JJ agents_NNS ,_, and_CC 39_CD %_NN
          were_VBD taking_VBG only_RB oral_JJ sulfonylureas_NNS ._. The_DT study_NN cohorts_NNS
          defined_VBN by_IN type_NN of_IN therapy_NN varied_VBD considerably_RB with_IN
          respect_NN to_TO several_JJ important_JJ demographic_JJ and_CC clinical_JJ
          characteristics_NNS ._. Compared_VBN to_TO those_DT using_VBG drug_NN therapy_NN ,_,
          the_DT non-drug_JJ therapy_NN group_NN was_VBD more_RBR likely_JJ to_TO be_VB female_JJ
          (_( 55_CD %_NN vs_NNS ._. 47_CD %_NN ;_: p_NN <_NN 0_CD ._. 001_CD )_) ,_, white_JJ (_( 76_CD %_NN vs_NNS ._. 67_CD %_NN :_: p_NN <_NN
          0_CD ._. 001_CD )_) ,_, and_CC to_TO have_VB no_DT comorbidities_NNS (_( 33_CD %_NN vs_NNS ._. 2_CD %_NN ;_: p_NN <_NN
          0_CD ._. 001_CD )_) ._. As_IN shown_VBN in_IN Table_NNP 1_CD ,_, insulin-managed_JJ patients_NNS
          were_VBD more_RBR likely_JJ to_TO be_VB female_JJ (_( 51_CD %_NN vs_NNS ._. 44_CD %_NN ,_, p_NN <_NN
          0_CD ._. 001_CD )_) ,_, of_IN younger_JJR average_JJ age_NN (_( 51_CD vs_NNS ._. 56_CD ;_: p_NN <_NN 0_CD ._. 001_CD )_) ,_,
          and_CC Black_NNP (_( 31_CD %_NN vs_NNS ._. 25_CD %_NN ;_: p_NN <_NN 0_CD ._. 001_CD )_) compared_VBN to_TO those_DT
          using_VBG sulfonylureas_NNS ._. They_PRP were_VBD also_RB less_RBR likely_JJ to_TO be_VB
          enrolled_VBN in_IN Medicare_NNP (_( 17_CD %_NN vs_NNS ._. 24_CD %_NN ;_: p_NN <_NN 0_CD ._. 001_CD )_) ,_, which_WDT
          was_VBD consistent_JJ with_IN the_DT differences_NNS in_IN age_NN ._. While_IN
          sulfonylurea-managed_JJ patients_NNS were_VBD more_RBR likely_JJ to_TO be_VB
          obese_NN (_( 55_CD %_NN vs_NNS ._. 46_CD %_NN ;_: p_NN <_NN 0_CD ._. 001_CD )_) ,_, insulin_NN patients_NNS had_VBD a_DT
          higher_JJR number_NN of_IN comorbidities_NNS ,_, on_IN average_JJ ,_, than_IN either_DT
          the_DT sulfonylurea_NN only_RB or_CC the_DT no_DT drug_NN group_NN (_( 3_CD ._. 1_LS vs_NNS ._. 2_CD ._. 8_CD
          vs_NNS ._. 1_CD ._. 6_CD ;_: respectively_RB ;_: p_NN <_NN 0_CD ._. 001_CD in_IN both_DT group_NN
          comparisons_NNS )_) ._. There_EX were_VBD no_DT significant_JJ (_( p_NN <_NN 0_CD ._. 05_CD )_)
          differences_NNS in_IN neighborhood_NN SES_NNP by_IN type_NN of_IN drug_NN
          therapy_NN ._.
          As_IN shown_VBN in_IN Table_NNP 2_CD ,_, insulin-managed_JJ patients_NNS had_VBD more_JJR
          health_NN center_NN visits_NNS on_IN average_JJ (_( 14_CD ._. 2_LS ±_NN 11_CD ._. 9_CD )_) than_IN those_DT
          using_VBG either_CC oral_JJ (_( 10_CD ._. 7_CD ±_NN 8_CD ._. 5_LS )_) or_CC no_DT drug_NN therapy_NN (_( 10_CD ._. 1_LS ±_NN
          8_CD ._. 8_CD )_) ;_: this_DT difference_NN was_VBD statistically_RB significant_JJ (_( p_NN
          <_NN 0_CD ._. 001_CD )_) ._. Compared_VBN to_TO sulfonylurea-managed_JJ patients_NNS ,_,
          insulin-managed_JJ were_VBD more_RBR likely_JJ to_TO have_VB been_VBN
          hospitalized_VBN during_IN the_DT study_NN period_NN (_( 20_CD %_NN vs_NNS ._. 13_CD %_NN ;_: p_NN <_NN
          0_CD ._. 001_CD )_) and_CC to_TO have_VB had_VBN an_DT emergency_NN room_NN visit_NN (_( 25_CD %_NN vs_NNS ._.
          17_CD %_NN ;_: p_NN <_NN 0_CD ._. 001_CD )_) ._.
        
        
          SMBG_NNP ,_, Lab_NNP Testing_NNP ,_, and_CC Glycemic_NNP Control_NNP
          SMBG_NNP frequency_NN was_VBD well_RB below_IN recommended_VBD guidelines_NNS
          for_IN both_DT insulin_NN and_CC sulfonylurea_NN patients_NNS (_( Table_NNP 2_LS )_) ._.
          Insulin-managed_NNP patients_NNS were_VBD more_RBR likely_JJ to_TO self-monitor_JJ
          compared_VBN to_TO those_DT using_VBG oral_JJ medications_NNS (_( 66_CD %_NN vs_NNS ._. 24_CD %_NN ;_: p_NN
          <_NN 0_CD ._. 001_CD )_) ._. However_RB ,_, regular_JJ SMBG_NNP was_VBD far_RB less_RBR prevalent_JJ
          among_IN insulin-managed_JJ and_CC sulfonylurea-managed_JJ patients_NNS
          (_( 22_CD %_NN vs_NNS ._. 7_CD %_NN respectively_RB ,_, p_NN <_NN 0_CD ._. 001_CD )_) ._. Only_RB 7_CD %_NN of_IN
          patients_NNS managed_VBN without_IN drugs_NNS used_VBD any_DT test_NN strips_NNS
          during_IN the_DT year_NN ._.
          Approximately_RB 77_CD %_NN of_IN drug_NN therapy_NN patients_NNS had_VBD at_IN
          least_JJS one_CD HbA_NNP 1_CD c_SYM lab_NN test_NN per_IN year_NN ._. In_IN contrast_NN ,_, fewer_JJR
          than_IN half_NN of_IN patients_NNS managed_VBN without_IN drugs_NNS were_VBD tested_VBN
          (_( 48_CD %_NN ,_, p_NN <_NN 0_CD ._. 001_CD )_) ._. Among_IN patients_NNS with_IN at_IN least_JJS one_CD lab_NN
          test_NN ,_, insulin-managed_JJ patients_NNS had_VBD higher_JJR average_JJ HbA_NNP 1_CD c_SYM
          levels_NNS (_( 8_CD ._. 9_CD %_NN test_NN value_NN ±_NN 1_CD ._. 7_CD %_NN )_) compared_VBN to_TO
          sulfonylurea-managed_JJ (_( 8_CD ._. 3_LS %_NN ±_NN 1_CD ._. 7_CD %_NN )_) and_CC non-drug_JJ managed_VBN
          (_( 7_CD ._. 1_LS %_NN ±_NN 1_CD ._. 3_CD %_NN )_) patients_NNS (_( p_NN <_NN 0_CD ._. 001_CD for_IN both_DT
          comparisons_NNS )_) ._. Over_IN half_NN (_( 58_CD %_NN )_) of_IN all_DT patients_NNS on_IN drug_NN
          therapy_NN who_WP were_VBD tested_VBN had_VBD at_IN least_JJS one_CD HbA_NNP 1_CD c_SYM value_NN
          greater_JJR than_IN 8_CD ._. 0_CD %_NN during_IN the_DT study_NN period_NN and_CC 17_CD %_NN of_IN
          those_DT not_RB on_IN drug_NN therapy_NN who_WP were_VBD tested_VBN had_VBD similarly_RB
          elevated_VBD glycemic_JJ levels_NNS (_( p_NN <_NN 0_CD ._. 01_CD )_) ._. There_EX were_VBD no_DT
          significant_JJ differences_NNS in_IN glycemic_JJ level_NN by_IN level_NN of_IN
          SMBG_NNP for_IN those_DT without_IN any_DT drug_NN therapy_NN and_CC for_IN patients_NNS
          using_VBG sulfonylureas_NNS ._. However_RB ,_, for_IN the_DT insulin-managed_JJ
          group_NN ,_, patients_NNS who_WP monitored_VBD regularly_RB were_VBD much_RB less_RBR
          likely_JJ to_TO be_VB in_IN very_RB poor_JJ control_NN (_( 14_CD %_NN with_IN HbA_NNP 1_CD c_SYM >_NN
          10_CD %_NN )_) compared_VBN to_TO patients_NNS with_IN no_DT test_NN strip_NN use_NN (_( 31_CD %_NN )_) or_CC
          with_IN irregular_JJ test_NN strip_NN use_NN (_( 32_CD %_NN )_) (_( p_NN <_NN 0_CD ._. 001_CD for_IN
          both_DT comparisons_NNS )_) ._.
        
        
          Predictors_NNP of_IN SMBG_NNP
          Results_NNS of_IN the_DT multivariate_NN analyses_NNS examining_VBG the_DT
          likelihood_NN of_IN any_DT SMBG_NNP are_VBP presented_VBN in_IN Table_NNP 3_CD ._. For_IN
          insulin-managed_JJ patients_NNS ,_, higher_JJR SES_NNP of_IN the_DT census_NN tract_NN
          was_VBD significantly_RB associated_VBN with_IN greater_JJR odds_NNS of_IN SMBG_NNP
          (_( Odds_NNS Ratio_NNP :_: 1_CD ._. 41_CD ;_: 95_CD %_NN Confidence_NNP Interval_NNP :_: 1_CD ._. 18_CD -_: 1_CD ._. 70_CD )_) as_IN
          hypothesized_VBN ._. Further_RB ,_, older_JJR age_NN (_( OR_NNP :_: 0_CD ._. 80_CD ;_: CI_NNP :_:
          0_CD ._. 70_CD -_: 0_CD ._. 91_CD )_) ,_, male_JJ gender_NN (_( OR_NNP :_: 0_CD ._. 69_CD ;_: CI_NNP :_: 0_CD ._. 52_CD -_: 0_CD ._. 90_CD )_) ,_, and_CC
          obesity_NN (_( OR_NNP :_: 0_CD ._. 64_CD ;_: CI_NNP :_: 0_CD ._. 44_CD -_: 0_CD ._. 95_CD )_) were_VBD significantly_RB
          associated_VBN with_IN lower_JJR odds_NNS of_IN SMBG_NNP ._. However_RB ,_, higher_JJR level_NN
          of_IN comorbidity_NN was_VBD associated_VBN with_IN greater_JJR odds_NNS of_IN SMBG_NNP ,_,
          an_DT effect_NN that_WDT ran_VBD counter_RB to_TO our_PRP$ hypothesis_NNS (_( OR_NNP :_: 1_CD ._. 63_CD ;_:
          CI_NNP :_: 1_CD ._. 21_CD -_: 2_CD ._. 20_CD )_) ._. Two_CD or_CC more_JJR laboratory_NN HbA_NNP 1_CD c_SYM tests_NNS (_( OR_NNP :_:
          1_CD ._. 60_CD ;_: CI_NNP :_: 1_CD ._. 19_CD -_: 2_CD ._. 14_CD )_) and_CC four_CD or_CC more_JJR physician_NN visits_NNS
          (_( OR_NNP :_: 1_CD ._. 80_CD ;_: CI_NNP :_: 1_CD ._. 16_CD -_: 2_CD ._. 81_CD )_) were_VBD also_RB significant_JJ
          correlates_NNS of_IN SMBG_NNP ._.
          As_IN in_IN the_DT insulin-managed_JJ group_NN ,_, higher_JJR SES_NNP of_IN the_DT
          census_NN tract_NN was_VBD significantly_RB associated_VBN with_IN greater_JJR
          odds_NNS of_IN any_DT SMBG_NNP among_IN patients_NNS using_VBG oral_JJ sulfonylureas_NNS
          (_( OR_NNP :_: 1_CD ._. 26_CD ;_: CI_NNP :_: 1_CD ._. 07_CD -_: 1_CD ._. 47_CD )_) ._. Older_JJR age_NN (_( OR_NNP :_: 0_CD ._. 85_CD ;_: CI_NNP :_:
          0_CD ._. 76_CD -_: 0_CD ._. 96_CD )_) was_VBD associated_VBN with_IN lower_JJR odds_NNS of_IN SMBG_NNP ._. Two_CD or_CC
          more_JJR HbA_NNP 1_CD c_SYM tests_NNS (_( OR_NNP :_: 1_CD ._. 45_CD ;_: CI_NNP :_: 1_CD ._. 14_CD -_: 1_CD ._. 86_CD )_) ,_, four_CD or_CC more_JJR
          physician_NN visits_NNS (_( OR_NNP :_: 2_CD ._. 06_CD ;_: CI_NNP :_: 1_CD ._. 40_CD -_: 3_CD ._. 01_CD )_) ,_, and_CC the_DT
          standard_JJ monthly_JJ dose_NN of_IN diabetes_NN medications_NNS (_( OR_NNP :_: 1_CD ._. 13_CD ;_:
          CI_NNP :_: 1_CD ._. 04_CD -_: 1_CD ._. 23_CD )_) were_VBD associated_VBN with_IN greater_JJR odds_NNS of_IN SMBG_NNP
          in_IN the_DT oral_JJ managed_VBN group_NN ._.
        
        
          Predictors_NNP of_IN Regularity_NNP of_IN SMBG_NNP
          The_DT only_JJ factors_VBZ significantly_RB associated_VBN with_IN regular_JJ
          SMBG_NNP for_IN the_DT insulin-managed_JJ group_NN were_VBD black_JJ race_NN (_( OR_NNP :_:
          0_CD ._. 46_CD ;_: CI_NNP :_: 0_CD ._. 26_CD -_: 0_CD ._. 81_CD )_) and_CC very_RB poor_JJ glycemic_JJ control_NN (_( OR_NNP :_:
          0_CD ._. 38_CD ;_: CI_NNP :_: 0_CD ._. 21_CD -_: 0_CD ._. 69_CD )_) ._. The_DT only_JJ covariate_NN identified_VBN as_IN a_DT
          significant_JJ predictor_NN of_IN regular_JJ SMBG_NNP in_IN the_DT
          sulfonylurea-managed_JJ group_NN was_VBD having_VBG two_CD or_CC more_JJR HbA_NNP 1_CD c_SYM
          tests_NNS (_( OR_NNP :_: 1_CD ._. 89_CD ;_: CI_NNP :_: 1_CD ._. 18_CD -_: 3_CD ._. 04_CD )_) ._. The_DT lack_NN of_IN significant_JJ
          predictors_NNS of_IN regular_JJ SMBG_NNP for_IN patients_NNS managed_VBN with_IN
          sulfonylureas_NNS may_MD be_VB due_JJ to_TO the_DT small_JJ proportion_NN (_( 7_CD %_NN )_) of_IN
          regular_JJ users_NNS in_IN this_DT group_NN ._.
        
      
      
        Discussion_NNP
        Our_PRP$ findings_NNS suggest_VBP that_WDT managed_VBD care_NN patients_NNS who_WP may_MD
        benefit_VB the_DT most_JJS from_IN intensive_JJ diabetes_NN management_NN may_MD be_VB
        least_JJS likely_JJ to_TO self-monitor_JJ blood_NN glucose_NN ._. Among_IN insulin_NN
        users_NNS ,_, older_JJR age_NN and_CC lower_JJR neighborhood_NN SES_NNP were_VBD associated_VBN
        with_IN lower_JJR odds_NNS of_IN any_DT SMBG_NNP ._. Further_RB ,_, black_JJ race_NN and_CC lack_NN
        of_IN glycemic_JJ control_NN were_VBD significantly_RB associated_VBN with_IN less_RBR
        frequent_JJ SMBG_NNP ,_, suggesting_VBG that_IN these_DT characteristics_NNS may_MD
        represent_VB significant_JJ barriers_NNS to_TO adherence_NN ._. For_IN patients_NNS
        using_VBG oral_JJ medications_NNS ,_, older_JJR age_NN and_CC lower_JJR neighborhood_NN
        SES_NNP were_VBD also_RB associated_VBN with_IN lower_JJR odds_NNS of_IN initiating_VBG
        SMBG_NNP ._.
        Our_PRP$ findings_NNS for_IN lower_JJR SES_NNP ,_, older_JJR age_NN ,_, and_CC black_JJ race_NN
        were_VBD consistent_JJ with_IN those_DT of_IN other_JJ studies_NNS ._. [_NN 4_CD 5_CD 6_CD ]_NN In_IN
        contrast_NN to_TO our_PRP$ hypothesis_NNS ,_, having_VBG multiple_JJ comorbidities_NNS
        was_VBD associated_VBN with_IN higher_JJR odds_NNS of_IN any_DT SMBG_NNP for_IN the_DT insulin_NN
        group_NN ._. However_RB ,_, this_DT result_NN may_MD be_VB consistent_JJ with_IN sicker_NN
        patients_NNS being_VBG urged_VBN to_TO monitor_VB more_RBR frequently_RB ._. There_EX was_VBD
        no_DT evidence_NN to_TO suggest_VB that_IN glycemic_JJ level_NN was_VBD associated_VBN
        with_IN SMBG_NNP except_IN for_IN patients_NNS using_VBG insulin_NN ._. Among_IN this_DT
        group_NN ,_, lack_NN of_IN glycemic_JJ control_NN (_( e_SYM ._. g_SYM ._. ,_, HbA_NNP 1_CD c_SYM >_NN 10_CD ._. 0_CD )_) was_VBD
        associated_VBN with_IN less_JJR than_IN half_PDT the_DT odds_NNS of_IN frequent_JJ SMBG_NNP ._.
        In_IN a_DT recent_JJ study_NN using_VBG data_NNS from_IN the_DT third_JJ National_NNP Health_NNP
        and_CC Nutritional_NNP Examination_NNP Survey_NNP (_( 1988_CD -_: 1994_CD )_) ,_, Harris_NNP [_NN 18_CD
        ]_NN found_VBD no_DT association_NN between_IN glycemic_JJ levels_NNS and_CC SMBG_NNP
        controlling_VBG for_IN type_NN of_IN drug_NN therapy_NN ._.
        There_EX are_VBP several_JJ limitations_NNS to_TO this_DT study_NN which_WDT merit_VBP
        discussion_NN ._. Most_JJS importantly_RB ,_, the_DT cross_NN sectional_JJ nature_NN of_IN
        the_DT study_NN design_NN prevents_VBZ us_PRP from_IN drawing_VBG causal_NN inferences_NNS
        about_IN the_DT relationship_NN between_IN the_DT chosen_VBN covariates_NNS and_CC
        SMBG_NNP behavior_NN ._. For_IN example_NN ,_, the_DT association_NN between_IN
        glycemic_JJ control_NN and_CC SMBG_NNP could_MD suggest_VB either_CC that_IN sicker_NN
        patients_NNS are_VBP less_RBR likely_JJ to_TO practice_VB SMBG_NNP or_CC that_IN patients_NNS
        who_WP practice_NN SMBG_NNP are_VBP more_RBR likely_JJ to_TO be_VB in_IN glycemic_JJ
        control_NN ._. Furthermore_RB ,_, as_IN most_JJS states_NNS now_RB mandate_NN coverage_NN
        of_IN home_NN monitoring_VBG equipment_NN ,_, the_DT impact_NN of_IN variations_NNS in_IN
        coverage_NN of_IN test_NN strips_NNS ,_, which_WDT may_MD cost_VB the_DT patient_NN more_JJR
        than_IN the_DT monitor_NN in_IN the_DT long_JJ run_NN ,_, may_MD be_VB a_DT more_RBR relevant_JJ
        topic_NN for_IN future_JJ studies_NNS ._. Also_RB ,_, more_JJR evidence_NN of_IN the_DT
        efficacy_NN of_IN SMBG_NNP for_IN patients_NNS with_IN Type_NNP 2_CD diabetes_NN is_VBZ
        needed_VBN ,_, especially_RB given_VBN the_DT potential_JJ importance_NN of_IN belief_NN
        in_IN the_DT efficacy_NN of_IN SMBG_NNP on_IN patient_NN behavior_NN ._. [_NN 13_CD ]_NN
        The_DT policy_NN to_TO cover_VB the_DT cost_NN of_IN home_NN glucose_NN monitors_VBZ at_IN
        this_DT HMO_NNP was_VBD implemented_VBN in_IN anticipation_NN of_IN the_DT DCCT_NNP
        results_NNS ._. In_IN further_JJ analyses_NNS of_IN the_DT policy_NN ,_, we_PRP found_VBD that_IN
        the_DT barriers_NNS to_TO SMBG_NNP identified_VBD in_IN this_DT study_NN did_VBD not_RB
        change_VB over_IN time_NN ._. Further_RB ,_, the_DT rate_NN of_IN SMBG_NNP changed_VBD very_RB
        little_JJ pre-_NN and_CC post-release_JJ of_IN the_DT DCCT_NNP findings_NNS and_CC the_DT
        policy_NN change_NN at_IN HPHC_NNP ._. Lastly_NNP ,_, similarities_NNS between_IN our_PRP$
        results_NNS and_CC those_DT from_IN more_RBR recent_JJ studies_NNS of_IN diabetes_NN
        self-management_JJ would_MD lend_VB additional_JJ support_NN to_TO our_PRP$
        conclusions_NNS regarding_VBG SMBG_NNP ._.
        Test_NN strip_NN dispensings_NNS are_VBP not_RB a_DT perfect_JJ measure_NN of_IN
        actual_JJ use_NN ,_, but_CC are_VBP likely_JJ to_TO be_VB more_JJR objective_NN than_IN
        self-reports_JJ ._. Also_RB ,_, failure_NN to_TO control_VB for_IN individual_JJ SES_NNP
        may_MD have_VB caused_VBN us_PRP to_TO overestimate_NN the_DT effect_NN of_IN
        neighborhood_NN SES_NNP ._. [_NN 24_CD 25_CD 26_CD ]_NN Still_RB ,_, other_JJ studies_NNS have_VBP
        found_VBN a_DT significant_JJ effect_NN of_IN neighborhood_NN SES_NNP on_IN
        individual_JJ health_NN and_CC mortality_NN even_RB when_WRB individual-level_JJ
        SES_NNP was_VBD controlled_VBN for_IN in_IN the_DT analyses_NNS ._. [_NN 27_CD 28_CD 29_CD 30_CD 31_CD 32_CD
        ]_NN Using_VBG an_DT index_NN similar_JJ to_TO our_PRP$ own_JJ ,_, Diez_NNP Roux_NNP et_CC al_NN [_NN 32_CD ]_NN
        recently_RB found_VBD that_IN living_VBG in_IN a_DT relatively_RB disadvantaged_JJ
        neighborhood_NN was_VBD associated_VBN with_IN greater_JJR incidence_NN of_IN
        coronary_JJ heart_NN disease_NN among_IN whites_NNS ,_, even_RB after_IN adjusting_VBG
        for_IN individual-level_JJ SES_NNP (_( Hazard_NNP Ratio_NNP :_: 1_CD ._. 6_CD ;_: 95_CD %_NN CI_NNP :_:
        1_CD ._. 1_CD -_: 1_CD ._. 2_LS )_) ._.
        Missing_NNP data_NNS may_MD have_VB introduced_VBN bias_NN into_IN our_PRP$ results_NNS ._.
        In_IN particular_JJ ,_, we_PRP only_RB included_VBD patients_NNS who_WP were_VBD
        continuously_RB enrolled_VBN ,_, thereby_RB limiting_VBG the_DT
        generalizability_NN of_IN our_PRP$ study_NN to_TO continuously_RB enrolled_VBD
        managed_VBN care_NN patients_NNS with_IN diabetes_NN ._. Further_RB ,_, approximately_RB
        22_CD %_NN of_IN the_DT study_NN population_NN did_VBD not_RB receive_VB an_DT HbA_NNP 1_CD c_SYM test_NN
        during_IN the_DT study_NN period_NN ,_, and_CC we_PRP anticipate_VBP that_IN patients_NNS
        with_IN lower_JJR average_JJ HbA_NNP 1_CD c_SYM levels_NNS were_VBD less_RBR likely_JJ to_TO have_VB
        had_VBD a_DT lab_NN test_NN ._. Race_NN data_NNS were_VBD unavailable_JJ for_IN 31_CD %_NN of_IN the_DT
        study_NN population_NN ._. However_RB ,_, in_IN a_DT comparison_NN of_IN race_NN data_NNS
        from_IN the_DT AMRS_NNP to_TO member_NN self-reports_JJ ,_, it_PRP was_VBD found_VBN that_IN
        blacks_NNS were_VBD only_RB slightly_RB more_RBR likely_JJ to_TO be_VB incorrectly_RB
        categorized_VBN (_( 2_CD %_NN of_IN blacks_NNS vs_NNS ._. 0_CD %_NN of_IN whites_NNS )_) or_CC counted_VBN as_IN
        missing_VBG (_( 38_CD %_NN of_IN blacks_NNS vs_NNS ._. 32_CD %_NN of_IN whites_NNS )_) relative_JJ to_TO
        whites_NNS (_( unpublished_JJ data_NNS ,_, Choo_NNP P_NN ,_, Platt_NNP R_NNP )_) ._.
        Data_NNS on_IN duration_NN of_IN diabetes_NN and_CC type_NN of_IN diabetes_NN ,_, which_WDT
        Karter_NNP et_CC al_NN [_NN 4_CD ]_NN identified_VBN as_IN predictors_NNS of_IN SMBG_NNP
        adherence_NN ,_, were_VBD not_RB consistently_RB available_JJ in_IN the_DT AMRS_NNP ._.
        Therefore_RB ,_, we_PRP controlled_VBD for_IN severity_NN of_IN illness_NN using_VBG type_NN
        and_CC intensity_NN of_IN drug_NN therapy_NN ,_, the_DT number_NN of_IN comorbidities_NNS ,_,
        glycemic_JJ level_NN ,_, and_CC health_NN service_NN use_NN ._. Still_RB ,_, it_PRP is_VBZ
        possible_JJ that_IN the_DT association_NN of_IN younger_JJR age_NN with_IN higher_JJR
        likelihood_NN of_IN SMBG_NNP may_MD in_IN part_VB reflect_VB differences_NNS in_IN type_NN
        or_CC duration_NN of_IN diabetes_NN among_IN insulin_NN users_NNS ._.
        The_DT greatest_JJS strength_NN of_IN our_PRP$ study_NN is_VBZ the_DT use_NN of_IN more_JJR
        objective_NN measures_NNS of_IN SMBG_NNP ._. Data_NNS on_IN test_NN strips_NNS are_VBP less_RBR
        vulnerable_JJ to_TO response_NN biases_NNS that_WDT may_MD hinder_VB the_DT detection_NN
        of_IN important_JJ relationships_NNS ._. Furthermore_RB ,_, the_DT structure_NN of_IN
        the_DT pharmacy_NN benefit_NN at_IN the_DT time_NN of_IN our_PRP$ study_NN makes_VBZ it_PRP very_RB
        likely_JJ that_IN all_DT test_NN strip_NN dispensings_NNS would_MD occur_VB in_IN
        health_NN plan_NN pharmacies_NNS ._. While_IN our_PRP$ data_NNS were_VBD gathered_VBN from_IN
        one_CD HMO_NNP ,_, the_DT large_JJ and_CC diverse_JJ patient_NN population_NN at_IN HPHC_NNP
        increases_VBZ the_DT generalizability_NN of_IN our_PRP$ results_NNS to_TO other_JJ
        managed_VBN care_NN settings_NNS ._.
      
      
        Conclusions_NNP
        While_IN the_DT efficacy_NN of_IN SMBG_NNP has_VBZ yet_RB to_TO be_VB demonstrated_VBN ,_,
        MCOs_NNP are_VBP under_IN increasing_VBG pressure_NN to_TO cover_VB the_DT cost_NN of_IN
        SMBG_NNP equipment_NN for_IN their_PRP$ patients_NNS and_CC to_TO improve_VB rates_NNS of_IN
        SMBG_NNP ._. Our_PRP$ findings_NNS provide_VBP troubling_JJ evidence_NN that_IN MCOs_NNP may_MD
        face_VB the_DT greatest_JJS challenges_NNS in_IN changing_VBG the_DT
        self-monitoring_JJ behavior_NN of_IN the_DT patients_NNS at_IN greatest_JJS risk_NN
        for_IN poor_JJ health_NN outcomes_NNS ._. Concern_NN over_IN health_NN disparities_NNS
        has_VBZ drawn_VBN increased_VBN attention_NN toward_IN community-based_JJ
        interventions_NNS for_IN diabetes_NN ._. Results_NNS of_IN ongoing_JJ
        interventions_NNS may_MD provide_VB managed_VBN care_NN organizations_NNS with_IN
        useful_JJ strategies_NNS for_IN reaching_VBG the_DT groups_NNS most_JJS at_IN risk_NN for_IN
        poor_JJ diabetes_NN outcomes_NNS ._. In_IN addition_NN ,_, well-controlled_JJ
        longitudinal_NN studies_NNS of_IN the_DT relationship_NN between_IN the_DT
        factors_NNS identified_VBN in_IN this_DT study_NN and_CC patterns_NNS of_IN SMBG_NNP and_CC
        self-management_JJ more_RBR generally_RB can_MD inform_VB future_JJ
        interventions_NNS ._.
      
      
        Competing_VBG Interests_NNP
        None_NN declared_VBD ._.
      
      
        Authors_NNP '_'' Contributions_NNP
        ASA_NNP participated_VBD in_IN the_DT design_NN and_CC analysis_NN of_IN the_DT study_NN
        and_CC drafted_VBD the_DT manuscript_NN ._. CM_NNP and_CC FZ_NNP participated_VBD in_IN the_DT
        design_NN and_CC coordination_NN of_IN the_DT study_NN and_CC performed_VBD the_DT
        statistical_JJ analysis_NN ._. SBS_NNP conceived_VBD of_IN the_DT study_NN and_CC
        participated_VBD in_IN its_PRP$ design_NN ._. MB_NNP lent_VBD clinical_JJ expertise_NN to_TO
        the_DT project_NN ._. DRD_NNP conceived_VBD of_IN the_DT study_NN and_CC participated_VBD in_IN
        its_PRP$ design_NN ._.
        All_DT authors_NNS read_VBP and_CC approved_VBD of_IN the_DT final_JJ
        manuscript_NN ._.
      
    
  
